The Windber Research Institute has made a number of administrative changes, GenomeWeb News has learned. Richard Mural joined the institute as chief scientific officer in September, replacing Michael Liebman, who has become executive director. In the past, Mural was director of scientific content and analysis at Celera Genomics.
Further, Michael Dunn joined Windber as its first chief medical officer in July. He is a retired brigadier general.
Richard Somiari has left his post as chief scientific officer and chief executive officer to found his own company (see below).
Richard Somiari has become president and chief scientific officer of Integrated Technologies & Services International - Biosciences in
Jochen Kohlhaas has become vice president for finance of Febit Biotech, the
Further, the company established a supervisory board and appointed the following members: Gerald Möller, former president and chief executive officer of Boehringer Mannheim; Michael Kranich, CEO of DH-Capital and OH Beteiligungen; Christof Hettich, a lawyer at Rittershaus; and Michael Meyer, CEO of Technostart.
MaryAnn Guerra has been promoted to chief operating officer of the Translational Genomics Research Institute of
Robert Young has been appointed to the board of directors of Human Genome Sciences, the company said today. He is the president of the Fox Chase Cancer Center in
Daniel Von Hoff has joined the oncology advisory board of Locus Pharmaceuticals, the Blue Bell, Pa.-based company said yesterday. He is the director of translational research at the Translational Genomics Research Institute in
Mahesh Krishnamurthy left his post as senior vice president of corporate development of Accelrys this summer, the company said in an SEC filing yesterday. A separation agreement with Krishnamurthy from October determines that he will receive $117,500 and reimbursement for up to six months for premiums paid for medical, dental, and vision insurance coverage.
Jennifer Gordon and Scott Familant have joined the intellectual property group in
Evan Steeghas become a contractor for senior strategy and business development at CMC Microsystems, GenomeWeb News has learned. He will help to lead the non-profit corporation further into healthcare and life sciences applications and partnerships. Previously, Steeg was president and CEO of Molecular Mining.
As part of Alpha Innotech's recent reverse merger with Xtrana, Haseeb Chaudhry has become chief executive officer and Darryl Ray president, chief operating officer, and acting chief financial officer of the merged company, Alpha Innotech. The following were appointed as members of the board of directors: Haseeb Chaudhry, Darryl Ray, Nagesh Mhatre, and William Snider. In addition, two continuing directors of Xtrana, Michael Bick and James Chamberlain, have joined the board.
In conjunction with the recent acquisition of Genaissance Pharmaceuticals by Clinical Data, Kevin Rakin and Joseph "Skip" Klein III have joined the board of directors of Clinical Data, the company said last week. Both were directors of Genaissance.
Jay Short has resigned as president and CEO of Diversa and has stepped down from the company's board, the San Diego-based company said last week. Edward Shonsey, Diversa's executive vice president of internal development, has been appointed as interim CEO.
Michael McGarrity has joined Nanosphere as chief marketing officer, the
Wylie Chenn has become regional director Asia/Pacific for Serologicals, the
David Gelfand has retired as vice president of the discovery research division and director of the program in core research of Roche Molecular Systems, GenomeWeb News has learned. He was based at Roche Molecular in
Promoted? Changing jobs?GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.